Rakovina Therapeutics

Publicly traded (RKV.V) company focused on the development of new cancer treatments based on novel DNA-damage response technologies.

Rakovina Therapeutics is a business in biotechnology, life science, oncology, founded in 2020.

Its activity falls under biotechnology, life science, oncology; the profile below is assembled from public directory data.

The company is listed at the Post_Ipo_Equity stage of development.

Its team size is recorded as c_00001_00010 employees.

Total disclosed funding stands at about $6.8M.

Website: www.rakovinatherapeutics.com